Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 110 articles: HTML format

Single Articles

May 2026
1. GHOSH D, White B, Lu X, Perricone M, et al
   Autophagy is essential for survival and function of polyploid giant cancer cells under therapeutic stress.
   Cancer Lett. 2026;646:218431.
   PubMed     Abstract available
   
   
   
2. NAND PK, Croucher DR, Khachigian LM
   Challenges in Triple Negative Breast Cancer Treatment and Therapeutic Potential of the Mitogen Activated Protein Kinase Pathway.
   Cancer Lett. 2026 May 2:218556. doi: 10.1016/j.canlet.2026.218556.
   PubMed     Abstract available
   
   
   
3. YUAN Q, Zhang H, Zhang N, Qian Y, et al
   BPHL promotes TNBC stemness by resolving R-loops via POLR2A lactylation inhibition and BARD1-mediated ubiquitination.
   Cancer Lett. 2026;645:218388.
   PubMed     Abstract available
   
   
   April 2026
4. ZHANG S, Shi Z, Du S, Zhu T, et al
   Integration of longitudinal MRI and biopsy whole slide images for early prediction of neoadjuvant therapy response and personalized management in breast cancer: A multicenter retrospective and prospective study.
   Cancer Lett. 2026;650:218508.
   PubMed     Abstract available
   
   
   
5. YING XH, Zhang KY, Jiang SH, Chen L, et al
   Integrated Genomic Profiling Identifies Predictive Biomarkers for Neoadjuvant Therapy Response in Chinese Breast Cancer Patients.
   Cancer Lett. 2026 Apr 11:218503. doi: 10.1016/j.canlet.2026.218503.
   PubMed     Abstract available
   
   
   
6. HONG L, Lee S, Frisbie L, Zhao Y, et al
   Nitroalkenes Exploit Dependence on Autophagy-Lysosome Pathway in PARPi-Resistant Triple Negative Breast Cancer.
   Cancer Lett. 2026 Apr 11:218504. doi: 10.1016/j.canlet.2026.218504.
   PubMed     Abstract available
   
   
   
7. LEU JS, Deng H, Tran HN, Wei X, et al
   Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis.
   Cancer Lett. 2026;649:218491.
   PubMed     Abstract available
   
   
   
8. SABIT H, Yadav AK, Salimy S, Sakr A, et al
   Integrating Multi-Omics and Artificial Intelligence for Personalized Breast Cancer Management: A Guide to Clinicians.
   Cancer Lett. 2026 Apr 3:218468. doi: 10.1016/j.canlet.2026.218468.
   PubMed     Abstract available
   
   
   March 2026
9. FABRIZIO FP, Pegreffi F, Leonardi R, Mazza M, et al
   Can Macrophages Predict Response to Neoadjuvant Therapy in Lung Cancer? A Lesson from Breast Cancer.
   Cancer Lett. 2026 Mar 17:218438. doi: 10.1016/j.canlet.2026.218438.
   PubMed    
   
   
   
10. GAO YY, Lou KL, Lin LL, Li CX, et al
    A NIR-? fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer.
    Cancer Lett. 2026;646:218429.
    PubMed     Abstract available
    
    
    
11. MOHOLKAR DN, Kandimalla R, Jeyabalan J, Singhal R, et al
    Exosomal Cannabidiol: A Promising Candidate for Targeted Oral Delivery against Breast Cancer.
    Cancer Lett. 2026 Mar 9:218416. doi: 10.1016/j.canlet.2026.218416.
    PubMed     Abstract available
    
    
    
12. DAI Y, Wu X, Cheng X, Shang J, et al
    tRF-1432 orchestrates RBMS1-IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer.
    Cancer Lett. 2026;646:218408.
    PubMed     Abstract available
    
    
    February 2026
13. GROZA P, Kumari K, Esteva-Socias M, Schott J, et al
    Fibrillarin-dependent 2'-O-methylation modulates RPS28 ribosome incorporation and oncogenic translation.
    Cancer Lett. 2026;639:218124.
    PubMed     Abstract available
    
    
    
14. YANG C, Liu J, Kang X, Wang Z, et al
    PANX1-mediated NLRP3 inflammasome activation promotes an adaptive doxorubicin resistance through IL-1beta signaling in breast cancer.
    Cancer Lett. 2026;645:218387.
    PubMed     Abstract available
    
    
    
15. WU CS, Chen HF, Huynh KT, Huang WC, et al
    Targeting PCK1 to overcome CDK4/6 inhibitor resistance for breast cancer therapy.
    Cancer Lett. 2026 Feb 24:218349. doi: 10.1016/j.canlet.2026.218349.
    PubMed     Abstract available
    
    
    
16. VERMA S, Singh V, Lang JE, Gupta S, et al
    Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics.
    Cancer Lett. 2026;645:218350.
    PubMed     Abstract available
    
    
    
17. HAUSMANN F, Kobayashi T, Maggs L, Meyer MN, et al
    Antimetastatic activity of B7-H3-targeted CAR T-cell therapy in triple-negative breast cancer.
    Cancer Lett. 2026;644:218345.
    PubMed    
    
    
    
18. XUE X, Ji D, Xue L, Tan Y, et al
    Spatially Resolved Transcriptomics Identifies Tumor-Stroma-Immune Networks and Therapeutic Targets in Endocrine-Resistant Advanced Breast Cancer Treated with Everolimus+Letrozole: Insights from the MIRACLE Trial.
    Cancer Lett. 2026 Feb 18:218327. doi: 10.1016/j.canlet.2026.218327.
    PubMed     Abstract available
    
    
    
19. ZHAO Z, Jia W, Li Z, Shi S, et al
    Targeting the SIN1 mediated TTK/LDHA-H3K18la-GLUT3 Axis Disrupts Metabolic-Epigenetic Crosstalk and Suppresses Progression in Hyperglycolytic Breast Cancer.
    Cancer Lett. 2026 Feb 16:218328. doi: 10.1016/j.canlet.2026.218328.
    PubMed     Abstract available
    
    
    January 2026
20. XIA F, Zhu X, Li X, Yi Q, et al
    FIG4 Downregulation-Arrested Autophagy-lysosomal Degradation of IL-18 Drives Lipid-Associated Macrophage Polarization and Immunotherapy Resistance in Triple-Negative Breast Cancer.
    Cancer Lett. 2026 Jan 21:218278. doi: 10.1016/j.canlet.2026.218278.
    PubMed     Abstract available
    
    
    
21. CROSS CB, Bowen JM, Leifert WR, Beale DJ, et al
    Pre-treatment Gut Microbiome and Salivary Metabolome Signatures Associate with Chemotherapy-Induced Cognitive Decline in Women with Breast Cancer: A Prospective Pilot Study.
    Cancer Lett. 2026 Jan 7:218234. doi: 10.1016/j.canlet.2025.218234.
    PubMed    
    
    
    December 2025
22. LI J, Li Z, Zhang X, Zhang H, et al
    Histone lactylation bridges metabolic reprogramming with chromatin-immune crosstalk in triple-negative breast cancer.
    Cancer Lett. 2025;639:218227.
    PubMed     Abstract available
    
    
    
23. SAFAEI M, Li YC, Chen CY, Hsieh PH, et al
    Targeting ephrin receptor A10 with antibody-drug conjugates for breast cancer.
    Cancer Lett. 2025;639:218225.
    PubMed     Abstract available
    
    
    
24. YOU Y, Wei L, Dai M, Zhao G, et al
    BMP9 potentiates immunotherapy in triple-negative breast cancer by suppressing Tregs infiltration via the PRKDC-CCL2 axis.
    Cancer Lett. 2025;639:218175.
    PubMed     Abstract available
    
    
    
25. VESUNA F, Winnard PT Jr, van Voss MH, Bol GM, et al
    Inhibition of DDX3 modulates immune signaling in aggressive breast cancers.
    Cancer Lett. 2025;634:218065.
    PubMed     Abstract available
    
    
    
26. DUAN F, Zhang C, Wu Z, Zhuang L, et al
    Copper Orchestrates Triple-negative Breast Cancer Progression via the STEAP3-dependent CDK16-JAK1 Activation.
    Cancer Lett. 2025 Dec 1:218192. doi: 10.1016/j.canlet.2025.218192.
    PubMed     Abstract available
    
    
    October 2025
27. DHRUBA SR, Sahni S, Wang B, Wu D, et al
    Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.
    Cancer Lett. 2025 Oct 30:218101. doi: 10.1016/j.canlet.2025.218101.
    PubMed     Abstract available
    
    
    
28. YANG X, Xia Z
    Commentary: Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.
    Cancer Lett. 2025 Oct 30:218108. doi: 10.1016/j.canlet.2025.218108.
    PubMed    
    
    
    
29. KRAWCZYNSKA N, Wang Y, Lim K, Das Gupta A, et al
    Neutrophils exposed to a cholesterol metabolite secrete extracellular vesicles that promote epithelial-mesenchymal transition and stemness in breast cancer cells.
    Cancer Lett. 2025 Oct 28:218105. doi: 10.1016/j.canlet.2025.218105.
    PubMed     Abstract available
    
    
    
30. YAZDI N, Pourjamal N, Katainen R, Vaananen J, et al
    Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates.
    Cancer Lett. 2025;630:217900.
    PubMed     Abstract available
    
    
    September 2025
31. TAN C, Lyu H, Ruan S, Wu Y, et al
    Subtype-specific HER3 enrichment in basal-like breast cancer is regulated via the GATA2/GATA3-FOXA1 axis.
    Cancer Lett. 2025 Sep 2:218001. doi: 10.1016/j.canlet.2025.218001.
    PubMed     Abstract available
    
    
    
32. LIU K, Hoover AR, Sun Y, Valerio TI, et al
    Anti-tumor effects on tumor-infiltrating natural killer cells by localized ablative immunotherapy and immune checkpoint inhibitors: An integrated and comparative study using scRNAseq analysis.
    Cancer Lett. 2025;627:217825.
    PubMed     Abstract available
    
    
    August 2025
33. LI C, Gao T, Zhao Q, Li Z, et al
    Inhibition of CPT1A activates the cGAS/STING pathway to enhance neutrophil-mediated tumor abrogation in triple-negative breast cancer.
    Cancer Lett. 2025;633:217991.
    PubMed     Abstract available
    
    
    July 2025
34. RUPP B, Nagpal N, Thanasiu B, Tuck K, et al
    Multiplex characterization of circulating tumor cells from ductal carcinoma in situ patients suggests early tumor dissemination.
    Cancer Lett. 2025;623:217703.
    PubMed     Abstract available
    
    
    
35. CAI MY, Yin P, Wang ZW, Huang YZ, et al
    Dual Regulation of FZD1/7 by IGF2BP3 Enhances Stem-like Properties and Carboplatin Resistance in Triple-Negative Breast Cancer.
    Cancer Lett. 2025 Jul 22:217944. doi: 10.1016/j.canlet.2025.217944.
    PubMed     Abstract available
    
    
    
36. ZHANG M, Tang C, Li S, Jiang X, et al
    NSUN2-mediated m(5)C modification of KDM6B mRNA enhances osteoclast differentiation and promotes breast cancer bone metastasis.
    Cancer Lett. 2025 Jul 19:217939. doi: 10.1016/j.canlet.2025.217939.
    PubMed     Abstract available
    
    
    
37. WANG SC, Shen YC, Pan MR, Ou-Yang F, et al
    Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in Taiwan.
    Cancer Lett. 2025 Jul 10:217912. doi: 10.1016/j.canlet.2025.217912.
    PubMed     Abstract available
    
    
    
38. DI RUSSO S, Borsatti GE, Bouzidi A, Liberati FR, et al
    NF-kappaB-mediated cytokine secretion and glutamate metabolic reprogramming converge in breast cancer brain tropism.
    Cancer Lett. 2025 Jul 8:217907. doi: 10.1016/j.canlet.2025.217907.
    PubMed     Abstract available
    
    
    
39. TAKAO S, Furumoto H, Furusawa A, Kano M, et al
    Preserved host immunity with intercellular adhesion molecule-1 (ICAM-1)-targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of triple-negative breast cancer and other malignancies.
    Cancer Lett. 2025 Jul 7:217906. doi: 10.1016/j.canlet.2025.217906.
    PubMed     Abstract available
    
    
    
40. CHICA-PARRADO MR, Kim GM, Uemoto Y, Napolitano F, et al
    Corrigendum to "Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer" [604 (2024) 217219 1-12].
    Cancer Lett. 2025 Jul 5:217891. doi: 10.1016/j.canlet.2025.217891.
    PubMed    
    
    
    June 2025
41. HAYKAL MM, Rodrigues-Ferreira S, El Botty R, Sourd L, et al
    Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers.
    Cancer Lett. 2025;620:217665.
    PubMed     Abstract available
    
    
    
42. SABIT H, Adel A, Abdelfattah MM, Ramadan RM, et al
    The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities.
    Cancer Lett. 2025;628:217865.
    PubMed     Abstract available
    
    
    
43. ZHOU W, Ding Q
    Advancing Neoadjuvant Therapy with Inetetamab for HER2-Positive Breast Cancer.
    Cancer Lett. 2025 Jun 5:217852. doi: 10.1016/j.canlet.2025.217852.
    PubMed     Abstract available
    
    
    May 2025
44. WU R, Yu S, Bi A, Li Y, et al
    Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer.
    Cancer Lett. 2025 May 24:217823. doi: 10.1016/j.canlet.2025.217823.
    PubMed     Abstract available
    
    
    
45. ELAYAPILLAI SP, Dogra S, Hladik C, Lausen J, et al
    Preferential Release of microRNAs via Extracellular Vesicles is Associated with Ductal Carcinoma In Situ to Invasive Breast Cancer Progression.
    Cancer Lett. 2025 May 17:217794. doi: 10.1016/j.canlet.2025.217794.
    PubMed     Abstract available
    
    
    
46. UEMOTO Y, A Lin CC, Wang B, Ye D, et al
    Corrigendum to "Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations" [619 1 (2025) 217668 1-13].
    Cancer Lett. 2025;626:217782.
    PubMed    
    
    
    
47. WALTER V, Koch A, Hillmann D, Dannehl D, et al
    Association of CMV Status with Response to Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer.
    Cancer Lett. 2025 May 10:217789. doi: 10.1016/j.canlet.2025.217789.
    PubMed    
    
    
    
48. ZUO WJ, Ma LX, Wang ZH, Cao XC, et al
    Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial.
    Cancer Lett. 2025 May 10:217785. doi: 10.1016/j.canlet.2025.217785.
    PubMed     Abstract available
    
    
    
49. LIU S, Chen H, Gagea M, Federico L, et al
    ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.
    Cancer Lett. 2025 May 6:217775. doi: 10.1016/j.canlet.2025.217775.
    PubMed     Abstract available
    
    
    
50. JIANG C, Qian Y, Bai X, Li S, et al
    SLC7A5/E2F1/PTBP1/PKM2 axis mediates progression and therapy effect of triple-negative breast cancer through the crosstalk of amino acid metabolism and glycolysis pathway.
    Cancer Lett. 2025;617:217612.
    PubMed     Abstract available
    
    
    April 2025
51. GRIMSLEY HE, Antczak M, Reddin IG, Weiler N, et al
    Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkers.
    Cancer Lett. 2025 Apr 27:217754. doi: 10.1016/j.canlet.2025.217754.
    PubMed     Abstract available
    
    
    
52. XIE Y, Xie J, Huang G, Zhang J, et al
    Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple negative breast cancer.
    Cancer Lett. 2025 Apr 21:217734. doi: 10.1016/j.canlet.2025.217734.
    PubMed     Abstract available
    
    
    
53. KUNDU M, Greer YE, Lobanov A, Ridnour L, et al
    TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.
    Cancer Lett. 2025;620:217692.
    PubMed     Abstract available
    
    
    March 2025
54. LI H, Chatla S, Liu X, Tian Z, et al
    ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.
    Cancer Lett. 2025;613:217505.
    PubMed     Abstract available
    
    
    
55. UEMOTO Y, Lin CA, Wang B, Ye D, et al
    Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.
    Cancer Lett. 2025;619:217668.
    PubMed     Abstract available
    
    
    
56. YOU X, Hu X, Sun Z, Xu W, et al
    Dual targeting PPARalpha and NPC1L1 metabolic vulnerabilities blocks tumorigenesis.
    Cancer Lett. 2025;612:217493.
    PubMed     Abstract available
    
    
    
57. GILON-ZALTSMAN O, Weidenfeld-Barenboim K, Samara H, Feuermann Y, et al
    Targeting dormant disseminated tumor cells and their permissive niche by pro-resolving mediators derived from resolution-phase macrophages.
    Cancer Lett. 2025;612:217468.
    PubMed     Abstract available
    
    
    February 2025
58. ZENG Z, Yi Z, Xu B
    The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients.
    Cancer Lett. 2025 Feb 19:217574. doi: 10.1016/j.canlet.2025.217574.
    PubMed     Abstract available
    
    
    
59. CHEN H, Lin L, Qiao Z, Pei Y, et al
    YTHDF3 drives tumor growth and metastasis by recruiting eIF4B to promote Notch2 translation in breast cancer.
    Cancer Lett. 2025;614:217534.
    PubMed     Abstract available
    
    
    January 2025
60. ZHANG R, Jiang WJ, Zhao S, Kang LJ, et al
    FOXF2 expression triggered by endocrine therapy orchestrates therapeutic resistance through reorganization of chromatin architecture in breast cancer.
    Cancer Lett. 2025 Jan 17:217463. doi: 10.1016/j.canlet.2025.217463.
    PubMed     Abstract available
    
    
    
61. TAN N, Xia C, Yan X, Cao M, et al
    Extending breast cancer screening beyond age 45-64 years in China: a cost-effectiveness analysis.
    Cancer Lett. 2025 Jan 13:217457. doi: 10.1016/j.canlet.2025.217457.
    PubMed     Abstract available
    
    
    
62. USAMA M, Hsu YC, Safaei M, Chen CY, et al
    Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells.
    Cancer Lett. 2025;611:217453.
    PubMed     Abstract available
    
    
    
63. WANG Y, Zhou X, Lei Y, Chu Y, et al
    Corrigendum to "NNMT contributes to high metastasis of triple negative breast cancer by enhancing PP2A/MEK/ERK/c-Jun/ABCA1 pathway mediated membrane fluidity"[Cancer Lett. 547 (2022) 215884].
    Cancer Lett. 2025 Jan 3:217424. doi: 10.1016/j.canlet.2024.217424.
    PubMed    
    
    
    December 2024
64. JIA Y, Chen Y, Chen M, He M, et al
    Oncogenic HJURP enhancer promotes the aggressive behavior of triple-negative breast cancer in association with p53/E2F1/FOXM1-axis.
    Cancer Lett. 2024 Dec 28:217423. doi: 10.1016/j.canlet.2024.217423.
    PubMed     Abstract available
    
    
    
65. WANG K, He Q, Jiang X, Wang T, et al
    Targeting UBE2T suppresses breast cancer stemness through CBX6-mediated transcriptional repression of SOX2 and NANOG.
    Cancer Lett. 2024 Dec 21:217409. doi: 10.1016/j.canlet.2024.217409.
    PubMed     Abstract available
    
    
    November 2024
66. MUGHAL MJ, Zhang Y, Li Z, Zhou S, et al
    TFAP2C-DDR1 Axis Regulates Resistance to CDK4/6 Inhibitor in Breast Cancer.
    Cancer Lett. 2024 Nov 25:217356. doi: 10.1016/j.canlet.2024.217356.
    PubMed     Abstract available
    
    
    
67. GERRATANA L, Davis AA, Foffano L, Reduzzi C, et al
    Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling.
    Cancer Lett. 2024 Nov 20:217325. doi: 10.1016/j.canlet.2024.217325.
    PubMed     Abstract available
    
    
    
68. LIU K, Hoover AR, Wang L, Sun Y, et al
    Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells.
    Cancer Lett. 2024;604:217267.
    PubMed     Abstract available
    
    
    October 2024
69. BHATTARAI PY, Kim G, Lim SC, Choi HS, et al
    METTL3-STAT5B interaction facilitates the co-transcriptional m(6)A modification of mRNA to promote breast tumorigenesis.
    Cancer Lett. 2024;603:217215.
    PubMed     Abstract available
    
    
    September 2024
70. CHIANG CH, Xu XH, Song J, Xanthavanij N, et al
    The incidence and risk of cardiovascular events associated with pembrolizumab in patients with breast cancer.
    Cancer Lett. 2024 Sep 25:217277. doi: 10.1016/j.canlet.2024.217277.
    PubMed    
    
    
    
71. YU L, Wei W, Lv J, Lu Y, et al
    FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem cell activity.
    Cancer Lett. 2024 Sep 19:217271. doi: 10.1016/j.canlet.2024.217271.
    PubMed     Abstract available
    
    
    
72. WINNARD PT JR, Vesuna F, Bol GM, Gabrielson KL, et al
    Targeting RNA Helicase DDX3X with a Small Molecule Inhibitor for Breast Cancer Bone Metastasis Treatment.
    Cancer Lett. 2024 Sep 19:217260. doi: 10.1016/j.canlet.2024.217260.
    PubMed     Abstract available
    
    
    
73. LIU X, Ma Z, Jing X, Wang G, et al
    The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer.
    Cancer Lett. 2024 Sep 12:217232. doi: 10.1016/j.canlet.2024.217232.
    PubMed     Abstract available
    
    
    
74. CHICA-PARRADO MR, Kim GM, Uemoto Y, Napolitano F, et al
    Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.
    Cancer Lett. 2024 Sep 5:217219. doi: 10.1016/j.canlet.2024.217219.
    PubMed     Abstract available
    
    
    
75. ZHANG Z, Zhao M, Wang Q, Wang X, et al
    Forkhead box protein FOXK1 disrupts the circadian rhythm to promote breast tumorigenesis in response to insulin resistance.
    Cancer Lett. 2024;599:217147.
    PubMed     Abstract available
    
    
    August 2024
76. SRIVASTAVA P, Jha S, Singh SK, Vyas H, et al
    Protease activated receptor-1 regulates mixed lineage kinase-3 to drive triple-negative breast cancer tumorigenesis.
    Cancer Lett. 2024;603:217200.
    PubMed     Abstract available
    
    
    
77. MA Y, Zhang H, Shen X, Yang X, et al
    Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy.
    Cancer Lett. 2024;598:217102.
    PubMed     Abstract available
    
    
    
78. LIU B, Liu Y, Yang S, Ye J, et al
    Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes phenotypic plasticity and endocrine resistance in ER(+) breast cancer.
    Cancer Lett. 2024;600:217179.
    PubMed     Abstract available
    
    
    
79. GU T, Vasilatos SN, Yin J, Qin Y, et al
    Restoration of TFPI2 by LSD1 Inhibition Suppresses Tumor Progression and Potentiates Antitumor Immunity in Breast Cancer.
    Cancer Lett. 2024 Aug 16:217182. doi: 10.1016/j.canlet.2024.217182.
    PubMed     Abstract available
    
    
    
80. VIDANA GAMAGE HE, Albright ST, Smith AJ, Farmer R, et al
    Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells.
    Cancer Lett. 2024;597:217086.
    PubMed     Abstract available
    
    
    
81. VIDANA GAMAGE HE, Shahoei SH, Wang Y, Jacquin E, et al
    NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors.
    Cancer Lett. 2024;597:217042.
    PubMed     Abstract available
    
    
    
82. REGUA AT, Bindal S, Najjar MK, Zhuang C, et al
    Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Cancer Lett. 2024;597:217023.
    PubMed     Abstract available
    
    
    
83. YANG Y, Hao X, Zhang J, Gao T, et al
    The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling.
    Cancer Lett. 2024 Aug 8:217157. doi: 10.1016/j.canlet.2024.217157.
    PubMed     Abstract available
    
    
    July 2024
84. LI M, Zhang L, Guan T, Huang L, et al
    Energy stress-activated AMPK phosphorylates Snail1 and suppresses its stability and oncogenic function.
    Cancer Lett. 2024;595:216987.
    PubMed     Abstract available
    
    
    
85. LIU Y, Yin S, Lu G, Du Y, et al
    The intersection of the nervous system and breast cancer.
    Cancer Lett. 2024;598:217132.
    PubMed     Abstract available
    
    
    
86. ZHANG H, Zhang L, He Y, Jiang D, et al
    PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.
    Cancer Lett. 2024 Jul 8:217112. doi: 10.1016/j.canlet.2024.217112.
    PubMed     Abstract available
    
    
    
87. PERDRIX ROSELL A, Maiques O, Martin JAJ, Chakravarty P, et al
    Corrigendum to "Early functional mismatch between breast cancer cells and their tumour microenvironment suppresses long term growth" [Cancer Lett. 544 (2022), 215800].
    Cancer Lett. 2024 Jul 1:217078. doi: 10.1016/j.canlet.2024.217078.
    PubMed    
    
    
    June 2024
88. WAN YX, Qi XW, Lian YY, Liu ZY, et al
    Electroacupuncture Facilitates Vascular Normalization by Inhibiting Glyoxalase1 in Endothelial Cells to Attenuate Glycolysis and Angiogenesis in Triple-Negative Breast Cancer.
    Cancer Lett. 2024 Jun 28:217094. doi: 10.1016/j.canlet.2024.217094.
    PubMed     Abstract available
    
    
    
89. YU Y, Cao WM, Cheng F, Shi Z, et al
    FOXK2 amplification promotes breast cancer development and chemoresistance.
    Cancer Lett. 2024 Jun 18:217074. doi: 10.1016/j.canlet.2024.217074.
    PubMed     Abstract available
    
    
    
90. LIU J, Zhai M, Chen Y, Wei Y, et al
    Acetylation-dependent deubiquitinase USP26 stabilizes BAG3 to promote breast cancer progression.
    Cancer Lett. 2024 Jun 14:217005. doi: 10.1016/j.canlet.2024.217005.
    PubMed     Abstract available
    
    
    
91. WANG S, Xu L, Wang D, Zhao S, et al
    YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation.
    Cancer Lett. 2024 Jun 11:217047. doi: 10.1016/j.canlet.2024.217047.
    PubMed     Abstract available
    
    
    
92. LI SY, Zhang N, Zhang H, Wang N, et al
    Deciphering the TCF19/miR-199a-5p/SP1/LOXL2 pathway: Implications for breast cancer metastasis and epithelial-mesenchymal transition.
    Cancer Lett. 2024;597:216995.
    PubMed     Abstract available
    
    
    
93. ANDRIANI L, Ling YX, Yang SY, Zhao Q, et al
    Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting the TOLLIP-mediated autophagic degradation of CIP2A.
    Cancer Lett. 2024 Jun 5:217008. doi: 10.1016/j.canlet.2024.217008.
    PubMed     Abstract available
    
    
    
94. OLUWALANA D, Adeleye KL, Krutilina RI, Chen H, et al
    Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer.
    Cancer Lett. 2024 Jun 5:217011. doi: 10.1016/j.canlet.2024.217011.
    PubMed     Abstract available
    
    
    
95. RIVERA-RAMOS A, Cruz-Hernandez L, Talaveron R, Sanchez-Montero MT, et al
    Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth.
    Cancer Lett. 2024;591:216879.
    PubMed     Abstract available
    
    
    May 2024
96. SONG Y, Ren S, Chen X, Li X, et al
    Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics.
    Cancer Lett. 2024;590:216847.
    PubMed     Abstract available
    
    
    
97. LV Y, Sun S, Zhang J, Wang C, et al
    Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription.
    Cancer Lett. 2024 May 24:216988. doi: 10.1016/j.canlet.2024.216988.
    PubMed     Abstract available
    
    
    
98. LIN Z, Chen L, Wang Y, Zhang T, et al
    Improving Ultrasound Diagnostic Precision for Breast Cancer and Adenosis with Modality-Specific Enhancement (MSE) - Breast Net.
    Cancer Lett. 2024 May 23:216977. doi: 10.1016/j.canlet.2024.216977.
    PubMed     Abstract available
    
    
    
99. BELLI S, Esposito D, Ascione CM, Messina F, et al
    EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Cancer Lett. 2024 May 22:216968. doi: 10.1016/j.canlet.2024.216968.
    PubMed     Abstract available
    
    
    April 2024
100. ZHANG Y, Tan Y, Yuan J, Tang H, et al
     circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer.
     Cancer Lett. 2024;592:216907.
     PubMed     Abstract available
     
     
     
101. WANG J, Fan P, Shen P, Fan C, et al
     XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
     Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
     PubMed     Abstract available
     
     
     
102. LI K, Lin H, Liu A, Qiu C, et al
     SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
     Cancer Lett. 2024;590:216842.
     PubMed     Abstract available
     
     
     
103. ORHAN E, Velazquez C, Tabet I, Fenou L, et al
     CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
     Cancer Lett. 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820.
     PubMed     Abstract available
     
     
     
104. BULLOCK KK, Shattuck-Brandt R, Scalise C, Luo W, et al
     Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
     Cancer Lett. 2024;586:216681.
     PubMed     Abstract available
     
     
     March 2024
105. YANG Z, Chen H, Yin S, Mo H, et al
     PGR-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells.
     Cancer Lett. 2024 Mar 29:216795. doi: 10.1016/j.canlet.2024.216795.
     PubMed     Abstract available
     
     
     
106. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
     Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
     Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
     PubMed     Abstract available
     
     
     
107. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
     Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
     Cancer Lett. 2024;584:216608.
     PubMed     Abstract available
     
     
     February 2024
108. WANG X, Deng X, Hu J, Zheng W, et al
     K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
     Cancer Lett. 2024 Feb 29:216764. doi: 10.1016/j.canlet.2024.216764.
     PubMed     Abstract available
     
     
     
109. SUN J, Du R, Li X, Liu C, et al
     CD63(+) cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20.
     Cancer Lett. 2024 Feb 23:216747. doi: 10.1016/j.canlet.2024.216747.
     PubMed     Abstract available
     
     
     
110. HAN BY, Chen C, Luo H, Lin CJ, et al
     Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.
     Cancer Lett. 2024 Feb 23:216763. doi: 10.1016/j.canlet.2024.216763.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum